CD8A and melanoma: Exploring the different types of T cells, Ribas and colleagues carried out an examination of biopsies from melanoma samples during pembrolizumab treatment [32] finding an increase in the frequency of memory T cells (CD8+/CD4–/CD45RO+) in patients with a good response to pembrolizumab.